Outcome MeasureOther

VAS

Visual Analogue Scale

8 Papers in Blossom

Outcome Data Across Studies

Reported results for VAS across 7 studies with quantitative data.

Outcome data across 25 study arm–timepoint observations
SD
Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
2012Secondary
S-ketamine(experimental)0125.4——
Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
2012Secondary
S-ketamine(experimental)0.031121.9——
Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
2012Secondary
S-ketamine(experimental)0.125123.1——
Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
2012Secondary
Midazolam(placebo)0125.8——
Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
2012Secondary
Midazolam(placebo)0.031124.4——
Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
2012Secondary
Midazolam(placebo)0.125124.3——
Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial
2016Secondary
Ketamine(experimental)02072.017.9—
Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial
2016Secondary
Diclofenac(active_comparator)02069.518.8—
Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial
2016Secondary
Ketamine(experimental)212055.729.90.690
Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial
2016Secondary
Diclofenac(active_comparator)212055.430.10.690

Papers Using VAS

Open Accessindividual

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial

In an open‑label Phase IIa trial (n-12), a single 10 mg intranasal dose of 5‑MeO‑DMT (BPL‑003) given alongside a 10‑week relapse‑prevention CBT programme was acceptable in safety and tolerability in people with moderate–severe alcohol use disorder. Over 12 weeks, participants showed large improvements in drinking (mean abstinent days rose from 33.2% to 80.8% and heavy drinking days fell from 56.2% to 13.2%), providing preliminary evidence of efficacy and supporting larger controlled trials.

Published
Journal
Addiction
Authors
Marsden, J., Kelleher, M., Dunbar, F., Ermakova, A. O., Mitcheson, L., Roberts, C., Rucker, J. J., Scott, G., Saeger, I., Small, F., Seynaeve, M.
Open Accessindividual

Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial

In a double‑blind, placebo‑controlled within‑participant randomised trial of 16 adults stratified by baseline nonconscious‑threat–evoked amygdala activity, 120 mg MDMA acutely reduced amygdala and subgenual ACC activity, increased sgACC–amygdala connectivity, and raised likability of threat expressions in the high‑reactivity subgroup (NTNA+) versus the low‑reactivity subgroup. These results indicate that baseline neuroimaging of negative affect circuitry can identify biomarkers to personalise MDMA‑based therapies.

Published
Journal
JAMA Network Open
Authors
Zhang, X., Hack, L. M., Bertrand, C., Hilton, R., Gray, N. J., Boyar, L., Laudie, J., Heifets, B. D., Suppes, T., Van Roessel, P. J., Rodriguez, C. I., Deisseroth, K., Knutson, B., Williams, L. M.
Open Accessindividual

Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects

In a randomized double‑blind placebo‑controlled crossover study in 16 healthy volunteers, oral mescaline (100–800 mg) produced dose‑dependent subjective and autonomic effects with dose‑proportional pharmacokinetics (Tmax ≈2 h, t1/2 ≈3.5 h) and increasing duration (6.4–14 h), with reduced tolerability and frequent nausea/emesis at 800 mg. Co‑administration of the 5‑HT2A antagonist ketanserin markedly attenuated and shortened the effects of 800 mg mescaline, indicating that its acute effects are primarily mediated by 5‑HT2A receptors.

Published
Journal
Translational Psychiatry
Authors
Klaiber, A., Schmid, Y., Becker, A. M., Straumann, I., Erne, L., Jelusic, A., Thomann, J., Luethi, D., Liechti, M. E.
Open Accessindividual

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder

This open-label study assessed the safety, tolerability, and efficacy of intravenous DMT (70mg/70kg followed by 210mg/70kg) in healthy participants (n=3) and participants with treatment-resistant major depressive disorder (n=7). DMT was well-tolerated in both groups while depression scores decreased significantly the day after receiving the high dose. Adverse events were mostly mild and were resolved within 20-30 minutes of injection.

Published
Journal
Neuropsychopharmacology
Authors
D’Souza, D. C., Syed, S. A., Safi-Aghdam, H., Cozzi, N. V., Ranganathan, M.
Open Accessindividual

Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial

This double-blind, placebo-controlled crossover trial (n=18) investigated the effects of intravenous ketamine (35 mg/70 kg) in adults with social anxiety disorder. It finds that ketamine resulted in a significantly greater reduction in anxiety symptoms compared with placebo on clinician-rated measures, although self-reported anxiety scores did not show a significant difference.

Published
Journal
Neuropsychopharmacology
Authors
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., Bloch, M. H.
Paywallindividual

Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial

This double-blind study (n=40) compared the efficacy and safety of oral ketamine and diclofenac as treatments of mild to moderate depression over a 6-week treatment period and found that ketamine resulted in significant reductions of depression scores above those achieved by diclofenac.

Published
Journal
Journal of Affective Disorders
Authors
Jafarinia, M., Afarideh, M., Tafakhori, A., Arbabi, M., Ghajar, A., Noorbala, A. A., Saravi, M. A., Agah, E., Akhondzadeh, S.

Quick Facts

Full Name
Visual Analogue Scale
Domain
Other
Papers Indexed
8
Score Range
0–100
Interpretation
Lower = better
Unit
mm
All Measures